Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vascula...
Main Authors: | Brandon M. Bordeau, Joseph P. Balthasar |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2021-08-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1881 |
Similar Items
-
Monoclonal War: The Antibody Arsenal and Targets for Expanded Application
by: Eric H. Rosenn, et al.
Published: (2023-09-01) -
Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01) -
First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors
by: Chiara Testa, et al.
Published: (2022-12-01) -
Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates [version 2; peer review: 2 approved, 1 approved with reservations]
by: Nidhal K. Maraie, et al.
Published: (2024-03-01) -
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
by: Marjorie A. Shapiro
Published: (2024-04-01)